Inhibikase Therapeutics (IKT) Invested Capital (2020 - 2026)
Inhibikase Therapeutics (IKT) has 7 years of Invested Capital data on record, last reported at $167.6 million in Q1 2026.
- On a quarterly basis, Invested Capital rose 95.35% to $167.6 million in Q1 2026 year-over-year; TTM through Mar 2026 was $167.6 million, a 95.35% increase, with the full-year FY2025 number at $172.9 million, up 82.05% from a year prior.
- Invested Capital reached $167.6 million in Q1 2026 per IKT's latest filing, down from $172.9 million in the prior quarter.
- Over the last five years, Invested Capital for IKT hit a ceiling of $172.9 million in Q4 2025 and a floor of -$385381.0 in Q3 2024.
- A 5-year average of $51.0 million and a median of $25.4 million in 2023 define the central range for Invested Capital.
- Peak YoY movement for Invested Capital: tumbled 102.54% in 2024, then surged 19015.9% in 2025.
- Tracing IKT's Invested Capital over 5 years: stood at $21.2 million in 2022, then plummeted by 46.37% to $11.4 million in 2023, then surged by 736.08% to $95.0 million in 2024, then surged by 82.05% to $172.9 million in 2025, then dropped by 3.06% to $167.6 million in 2026.
- Business Quant data shows Invested Capital for IKT at $167.6 million in Q1 2026, $172.9 million in Q4 2025, and $72.9 million in Q3 2025.